Advertisement
Advertisement
U.S. markets open in 4 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Vallon Pharmaceuticals, Inc. (VLON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3997+0.0046 (+1.16%)
At close: 04:00PM EDT
0.3998 +0.00 (+0.03%)
After hours: 07:59PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update. Second Quarter 2022 Highlights Engaged Ladenburg Thalmann & Co. Inc. for an eval

  • GlobeNewswire

    Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

    PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,700,000 s

  • GlobeNewswire

    Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

    PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the Company’s proprietary abuse-deterrent formulation of immediate-release dextroam

Advertisement
Advertisement